5-HT3受体拮抗剂缓解胃癌晚期患者介入治疗消化道反应的效果

Effect of 5-HT3 Receptor Antagonist on Gastrointestinal Response in Patients with Advanced Gastric Cancer Treated by Interventional Therapy

目的:探究胃癌晚期患者行肿瘤介入治疗中应用5-HT3受体拮抗剂的临床价值。方法:选取2016年1月-2017年12月在北海市人民医院肿瘤科接受介入治疗的120例胃癌晚期患者作为研究对象,采用随机数字表法将研究对象随机分为对照组和试验组,各60例,所有患者均接受肿瘤介入治疗,试验组患者在肿瘤介入治疗前15 min应用5-HT3受体拮抗剂,比较两组患者术中和术后急性胃肠道反应的发生情况,并观察治疗结束后两组患者的KPS评分。结果:术中及术后12 h两组患者急性胃肠道反应发生率比较差异无统计学意义(P>0.05);术后1 d和术后3 d试验组急性胃肠道反应发生率为75.00%和56.67%,分别低于对照组的86.67%和75.00%,差异有统计学意义(P<0.05);治疗结束后试验组患者KPS评分(70.90±6.23)分,明显高于对照组的(64.83±6.12)分,差异有统计学意义(P<0.05)。结论:动脉应用5-HT3受体拮抗剂可有效控制因肿瘤介入治疗而引发的胃肠道副作用,提升胃癌患者的生存质量。建议在介入治疗前15 min时注入5-HT3受体拮抗剂,以获得更好疗效。

Objective:To explore the clinical value of 5-HT3 receptor antagonists in patients with advanced gastric cancer undergoing tumor interventional therapy.Method:120 patients with advanced gastric cancer who underwent interventional therapy in the Oncology Department of Beihai People’s Hospital from January 2016 to December 2017 were selected as subjects.The subjects were randomly divided into control group and experimental group by 60 cases using random number table method,All patients underwent tumor interventional therapy.Patients in the experimental group were treated with 5-HT3 receptor antagonist 15 min before tumor intervention.Compared the occurrence of acute gastrointestinal reactions during and after surgery in the two groups of patients.The KPS scores of the two groups of patients after the treatment were observed.Result:There was no significant difference in the incidence of acute gastrointestinal reactions between the two groups during the operation and 12 hours after operation(P>0.05).The incidence of acute gastrointestinal reactions was 75.00% and 56.67% in the experimental group 1 d and 3 d after surgery,lower than 86.67% and 75.00% in the control group,the difference was statistically significant(P<0.05).After treatment,the KPS score was(70.90±6.23)points in the experimental group was significantly higher than(64.83±6.12)points in the control group,the difference was statistically significant(P<0.05).Conclusion:Arterial application of 5-HT3 receptor antagonist can effectively control the gastrointestinal side effects caused by interventional therapy for cancer and improve the quality of life of patients with gastric cancer.And it is suggested that 5-HT3 receptor antagonist be injected 15 minutes before interventional therapy to obtain better therapeutic effect.